# Pioglitazone

## Actos 30mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OACT3                                                                                                                                                                                                                                                                                                                                                                       |
| Indications        | Monotherapy or in combination with sulphonylureas， metformin or insulin in patients with type II diabetes.                                                                                                                                                                                                                                                                 |
| Dosing             | 15-30 mg once daily， max 45 mg/day.                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Type 1 diabetes， diabetic ketoacidosis. Active hepatic disease or ALT levels > 2.5 times the upper limit of normal. NYHA class III or IV heart failure.                                                                                                                                                                                                                    |
| Adverse Effects    | Edema， upper respiratory tract infection， headache， myalgia. Cardiovascular: Edema (4.8% to 15.3% ) Endocrine metabolic: Weight gain Hematologic: Anemia (less than or equal to 2% ) Musculoskeletal: Fracture of bone (5.1% )， Myalgia (5.4%) Neurologic: Headache (9.1% ) Respiratory: Pharyngitis (5.1% )， Sinusitis (6.3% )， Upper respiratory infection (13.2% ) |
| Pregnancy          | No (limited) human data – animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                               |

